Annual EBITDA
-$7.17 M
+$2.87 M+28.63%
December 31, 2023
Summary
- As of February 7, 2025, TTNP annual EBITDA is -$7.17 million, with the most recent change of +$2.87 million (+28.63%) on December 31, 2023.
- During the last 3 years, TTNP annual EBITDA has fallen by -$106.00 thousand (-1.50%).
- TTNP annual EBITDA is now -251.80% below its all-time high of $4.72 million, reached on December 31, 2016.
Performance
TTNP EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$754.00 K
+$1.32 M+63.59%
September 30, 2024
Summary
- As of February 7, 2025, TTNP quarterly EBITDA is -$754.00 thousand, with the most recent change of +$1.32 million (+63.59%) on September 30, 2024.
- Over the past year, TTNP quarterly EBITDA has increased by +$1.17 million (+60.89%).
- TTNP quarterly EBITDA is now -105.63% below its all-time high of $13.40 million, reached on December 31, 1997.
Performance
TTNP Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$5.81 M
+$1.28 M+18.04%
September 30, 2024
Summary
- As of February 7, 2025, TTNP TTM EBITDA is -$5.81 million, with the most recent change of +$1.28 million (+18.04%) on September 30, 2024.
- Over the past year, TTNP TTM EBITDA has increased by +$1.35 million (+18.86%).
- TTNP TTM EBITDA is now -189.06% below its all-time high of $6.53 million, reached on June 30, 2016.
Performance
TTNP TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TTNP EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +28.6% | +60.9% | +18.9% |
| 3 y3 years | -1.5% | +69.7% | +35.7% |
| 5 y5 years | +9.1% | +70.8% | +8.9% |
TTNP EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +28.6% | at high | +70.9% | at high | +42.1% |
| 5 y | 5-year | -14.1% | +28.6% | -114.2% | +75.3% | -1342.7% | +42.1% |
| alltime | all time | -251.8% | +76.5% | -105.6% | +94.1% | -189.1% | +81.1% |
Titan Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$754.00 K(-63.6%) | -$5.81 M(-18.0%) |
| Jun 2024 | - | -$2.07 M(+95.2%) | -$7.09 M(+7.9%) |
| Mar 2024 | - | -$1.06 M(-45.0%) | -$6.57 M(-8.3%) |
| Dec 2023 | -$7.17 M(-28.6%) | -$1.93 M(-5.2%) | -$7.17 M(-8.2%) |
| Sep 2023 | - | -$2.03 M(+31.3%) | -$7.80 M(-6.7%) |
| Jun 2023 | - | -$1.55 M(-6.3%) | -$8.36 M(-9.1%) |
| Mar 2023 | - | -$1.65 M(-35.5%) | -$9.21 M(-8.3%) |
| Dec 2022 | -$10.04 M(+9.9%) | -$2.57 M(-1.1%) | -$10.04 M(+1.3%) |
| Sep 2022 | - | -$2.60 M(+8.5%) | -$9.91 M(+8.1%) |
| Jun 2022 | - | -$2.39 M(-3.9%) | -$9.17 M(+1.4%) |
| Mar 2022 | - | -$2.49 M(+2.1%) | -$9.04 M(-1.1%) |
| Dec 2021 | -$9.13 M(+29.4%) | -$2.44 M(+31.5%) | -$9.14 M(+16.7%) |
| Sep 2021 | - | -$1.85 M(-18.3%) | -$7.83 M(+10.5%) |
| Jun 2021 | - | -$2.27 M(-12.3%) | -$7.09 M(+11.1%) |
| Mar 2021 | - | -$2.58 M(+129.2%) | -$6.38 M(-6.8%) |
| Dec 2020 | -$7.06 M(+12.4%) | -$1.13 M(+1.6%) | -$6.85 M(+1598.8%) |
| Sep 2020 | - | -$1.11 M(-28.8%) | -$403.00 K(-77.5%) |
| Jun 2020 | - | -$1.56 M(-48.9%) | -$1.79 M(-64.9%) |
| Mar 2020 | - | -$3.05 M(-157.4%) | -$5.12 M(-18.5%) |
| Dec 2019 | -$6.28 M(-20.4%) | $5.32 M(-312.4%) | -$6.28 M(-57.6%) |
| Sep 2019 | - | -$2.50 M(-48.7%) | -$14.82 M(+4.7%) |
| Jun 2019 | - | -$4.88 M(+15.9%) | -$14.15 M(+44.4%) |
| Mar 2019 | - | -$4.21 M(+30.7%) | -$9.80 M(+24.3%) |
| Dec 2018 | -$7.88 M(-44.0%) | -$3.22 M(+75.3%) | -$7.88 M(-0.5%) |
| Sep 2018 | - | -$1.84 M(+249.0%) | -$7.93 M(-21.2%) |
| Jun 2018 | - | -$527.00 K(-77.0%) | -$10.05 M(-22.9%) |
| Mar 2018 | - | -$2.29 M(-29.7%) | -$13.04 M(-7.4%) |
| Dec 2017 | -$14.09 M(-398.4%) | -$3.27 M(-17.7%) | -$14.09 M(+0.8%) |
| Sep 2017 | - | -$3.96 M(+12.7%) | -$13.98 M(+11.5%) |
| Jun 2017 | - | -$3.52 M(+5.5%) | -$12.53 M(-501.5%) |
| Mar 2017 | - | -$3.34 M(+5.7%) | $3.12 M(-33.9%) |
| Dec 2016 | $4.72 M(-173.7%) | -$3.16 M(+25.1%) | $4.72 M(-17.5%) |
| Sep 2016 | - | -$2.52 M(-120.8%) | $5.72 M(-12.4%) |
| Jun 2016 | - | $12.14 M(-798.3%) | $6.53 M(-198.7%) |
| Mar 2016 | - | -$1.74 M(-19.4%) | -$6.61 M(+3.3%) |
| Dec 2015 | -$6.40 M(+105.0%) | -$2.16 M(+25.8%) | -$6.40 M(+18.3%) |
| Sep 2015 | - | -$1.71 M(+70.7%) | -$5.41 M(+24.5%) |
| Jun 2015 | - | -$1.00 M(-34.2%) | -$4.34 M(+14.3%) |
| Mar 2015 | - | -$1.53 M(+31.0%) | -$3.80 M(+21.8%) |
| Dec 2014 | -$3.12 M(+298.2%) | -$1.17 M(+79.5%) | -$3.12 M(+24.3%) |
| Sep 2014 | - | -$649.00 K(+40.5%) | -$2.51 M(+26.6%) |
| Jun 2014 | - | -$462.00 K(-45.4%) | -$1.98 M(+9.8%) |
| Mar 2014 | - | -$846.00 K(+52.7%) | -$1.81 M(+130.4%) |
| Dec 2013 | -$784.00 K(-90.6%) | -$554.00 K(+357.9%) | -$784.00 K(+17.5%) |
| Sep 2013 | - | -$121.00 K(-57.5%) | -$667.00 K(-79.1%) |
| Jun 2013 | - | -$285.00 K(-261.9%) | -$3.20 M(-31.2%) |
| Mar 2013 | - | $176.00 K(-140.3%) | -$4.65 M(-44.8%) |
| Dec 2012 | -$8.35 M(-20.3%) | -$437.00 K(-83.5%) | -$8.42 M(-3.7%) |
| Sep 2012 | - | -$2.65 M(+52.9%) | -$8.74 M(+8.7%) |
| Jun 2012 | - | -$1.74 M(-51.7%) | -$8.04 M(-23.4%) |
| Mar 2012 | - | -$3.60 M(+373.0%) | -$10.50 M(+0.2%) |
| Dec 2011 | -$10.47 M(+72.5%) | -$760.00 K(-61.0%) | -$10.47 M(-24.2%) |
| Sep 2011 | - | -$1.95 M(-53.5%) | -$13.81 M(+15.3%) |
| Jun 2011 | - | -$4.19 M(+17.3%) | -$11.98 M(+26.2%) |
| Mar 2011 | - | -$3.57 M(-12.8%) | -$9.49 M(+56.3%) |
| Dec 2010 | -$6.07 M(+7.5%) | -$4.10 M(+3464.3%) | -$6.07 M(+81.7%) |
| Sep 2010 | - | -$115.00 K(-93.2%) | -$3.34 M(-30.0%) |
| Jun 2010 | - | -$1.70 M(+1005.8%) | -$4.77 M(+0.3%) |
| Mar 2010 | - | -$154.00 K(-88.8%) | -$4.76 M(-15.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2009 | -$5.65 M(-68.9%) | -$1.37 M(-11.4%) | -$5.65 M(+32.0%) |
| Sep 2009 | - | -$1.55 M(-8.5%) | -$4.28 M(-50.8%) |
| Jun 2009 | - | -$1.69 M(+62.9%) | -$8.70 M(-41.2%) |
| Mar 2009 | - | -$1.04 M(-82.6%) | -$14.80 M(-43.0%) |
| Sep 2008 | - | -$5.97 M(-23.5%) | -$25.97 M(+6.0%) |
| Jun 2008 | - | -$7.79 M(+32.2%) | -$24.51 M(+18.7%) |
| Mar 2008 | - | -$5.90 M(-6.6%) | -$20.65 M(+13.8%) |
| Dec 2007 | -$18.14 M(+13.0%) | -$6.31 M(+40.3%) | -$18.14 M(+19.4%) |
| Sep 2007 | - | -$4.50 M(+14.4%) | -$15.20 M(+0.3%) |
| Jun 2007 | - | -$3.94 M(+15.8%) | -$15.16 M(+2.8%) |
| Mar 2007 | - | -$3.40 M(+0.9%) | -$14.74 M(-8.2%) |
| Dec 2006 | -$16.06 M(-29.1%) | -$3.37 M(-24.5%) | -$16.06 M(-4.8%) |
| Sep 2006 | - | -$4.46 M(+26.7%) | -$16.87 M(-10.4%) |
| Jun 2006 | - | -$3.52 M(-25.3%) | -$18.84 M(-10.5%) |
| Mar 2006 | - | -$4.71 M(+12.6%) | -$21.04 M(-7.1%) |
| Dec 2005 | -$22.65 M(-10.0%) | -$4.18 M(-34.8%) | -$22.65 M(-11.3%) |
| Sep 2005 | - | -$6.42 M(+12.2%) | -$25.53 M(+1.3%) |
| Jun 2005 | - | -$5.72 M(-9.4%) | -$25.21 M(+0.5%) |
| Mar 2005 | - | -$6.32 M(-10.6%) | -$25.09 M(-0.3%) |
| Dec 2004 | -$25.16 M(-6.3%) | -$7.07 M(+15.9%) | -$25.16 M(+1.1%) |
| Sep 2004 | - | -$6.10 M(+8.8%) | -$24.88 M(+2.3%) |
| Jun 2004 | - | -$5.61 M(-12.1%) | -$24.31 M(-4.2%) |
| Mar 2004 | - | -$6.38 M(-6.0%) | -$25.38 M(+0.2%) |
| Dec 2003 | -$26.84 M(-11.8%) | -$6.79 M(+22.7%) | -$25.34 M(-6.3%) |
| Sep 2003 | - | -$5.53 M(-17.1%) | -$27.03 M(-8.4%) |
| Jun 2003 | - | -$6.68 M(+5.3%) | -$29.51 M(-4.1%) |
| Mar 2003 | - | -$6.34 M(-25.2%) | -$30.77 M(+1.1%) |
| Dec 2002 | -$30.43 M(+29.5%) | -$8.48 M(+5.8%) | -$30.43 M(+2.6%) |
| Sep 2002 | - | -$8.01 M(+0.9%) | -$29.65 M(+5.8%) |
| Jun 2002 | - | -$7.94 M(+32.4%) | -$28.02 M(+18.9%) |
| Mar 2002 | - | -$6.00 M(-22.1%) | -$23.56 M(+0.3%) |
| Dec 2001 | -$23.50 M(+25.4%) | -$7.70 M(+20.6%) | -$23.50 M(+10.4%) |
| Sep 2001 | - | -$6.38 M(+83.2%) | -$21.28 M(+6.3%) |
| Jun 2001 | - | -$3.48 M(-41.3%) | -$20.02 M(-0.6%) |
| Mar 2001 | - | -$5.94 M(+8.5%) | -$20.14 M(+7.8%) |
| Dec 2000 | -$18.74 M(+62.9%) | -$5.47 M(+6.7%) | -$18.69 M(+15.3%) |
| Sep 2000 | - | -$5.13 M(+42.3%) | -$16.21 M(+20.2%) |
| Jun 2000 | - | -$3.60 M(-19.6%) | -$13.49 M(+3.9%) |
| Mar 2000 | - | -$4.48 M(+49.4%) | -$12.98 M(+15.4%) |
| Dec 1999 | -$11.50 M(+3.6%) | -$3.00 M(+25.0%) | -$11.25 M(-3.4%) |
| Sep 1999 | - | -$2.40 M(-22.6%) | -$11.65 M(-2.5%) |
| Jun 1999 | - | -$3.10 M(+12.6%) | -$11.95 M(+6.2%) |
| Mar 1999 | - | -$2.75 M(-19.0%) | -$11.25 M(+2.3%) |
| Dec 1998 | -$11.10 M(+50.0%) | -$3.40 M(+25.9%) | -$11.00 M(-289.6%) |
| Sep 1998 | - | -$2.70 M(+12.5%) | $5.80 M(+20.8%) |
| Jun 1998 | - | -$2.40 M(-4.0%) | $4.80 M(+50.0%) |
| Mar 1998 | - | -$2.50 M(-118.7%) | $3.20 M(-145.1%) |
| Dec 1997 | -$7.40 M(-26.7%) | $13.40 M(-462.2%) | -$7.10 M(-70.4%) |
| Sep 1997 | - | -$3.70 M(-7.5%) | -$24.00 M(+5.7%) |
| Jun 1997 | - | -$4.00 M(-68.8%) | -$22.70 M(+7.6%) |
| Mar 1997 | - | -$12.80 M(+265.7%) | -$21.10 M(+115.3%) |
| Dec 1996 | -$10.10 M(+11.0%) | -$3.50 M(+45.8%) | -$9.80 M(-38.0%) |
| Sep 1996 | - | -$2.40 M(0.0%) | -$15.80 M(+18.8%) |
| Jun 1996 | - | -$2.40 M(+60.0%) | -$13.30 M(+23.1%) |
| Mar 1996 | - | -$1.50 M(-84.2%) | -$10.80 M(+17.4%) |
| Dec 1995 | -$9.10 M | -$9.50 M(-9600.0%) | -$9.20 M(-3166.7%) |
| Sep 1995 | - | $100.00 K(0.0%) | $300.00 K(+50.0%) |
| Jun 1995 | - | $100.00 K(0.0%) | $200.00 K(+100.0%) |
| Mar 1995 | - | $100.00 K | $100.00 K |
FAQ
- What is Titan Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Titan Pharmaceuticals?
- What is Titan Pharmaceuticals annual EBITDA year-on-year change?
- What is Titan Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Titan Pharmaceuticals?
- What is Titan Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Titan Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Titan Pharmaceuticals?
- What is Titan Pharmaceuticals TTM EBITDA year-on-year change?
What is Titan Pharmaceuticals annual EBITDA?
The current annual EBITDA of TTNP is -$7.17 M
What is the all time high annual EBITDA for Titan Pharmaceuticals?
Titan Pharmaceuticals all-time high annual EBITDA is $4.72 M
What is Titan Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, TTNP annual EBITDA has changed by +$2.87 M (+28.63%)
What is Titan Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of TTNP is -$754.00 K
What is the all time high quarterly EBITDA for Titan Pharmaceuticals?
Titan Pharmaceuticals all-time high quarterly EBITDA is $13.40 M
What is Titan Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, TTNP quarterly EBITDA has changed by +$1.17 M (+60.89%)
What is Titan Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of TTNP is -$5.81 M
What is the all time high TTM EBITDA for Titan Pharmaceuticals?
Titan Pharmaceuticals all-time high TTM EBITDA is $6.53 M
What is Titan Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, TTNP TTM EBITDA has changed by +$1.35 M (+18.86%)